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Abstract 
 
The balance of excitatory and inhibitory neurotransmitters in the brain affects both neural responses and 
behaviour in humans and animals. Here we investigated whether dietary intervention aimed at increasing 
levels of the inhibitory neurotransmitter GABA can influence neural responses to basic sensory stimuli. 
Using a steady-state EEG paradigm, we found that the neural response to visual patterns was reduced in 
individuals who consumed a yeast-extract product rich in substances associated with the production of 
GABA (glutamate and B vitamins), but not in a control group who consumed a placebo substance (N=14 
per group). This demonstrates that the balance of excitation and inhibition in the brain can be influenced 
by dietary interventions, suggesting possible clinical benefits in conditions (e.g. epilepsy) where 
inhibition is abnormal. 
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1 Introduction 
 
The healthy brain depends on a delicate balance 
of excitation and inhibition governed by 
neurotransmitters such as gamma-aminobutyric 
acid (GABA). Atypical levels of GABA have 
been associated with disorders such as epilepsy 
(Petroff et al., 1996), autism (Robertson et al., 
2016), anxiety (Nemeroff, 2003) and 
depression (Honig et al., 1988), suggesting 
potential therapeutic benefits to modulating its 
concentration. Although dietary supplements 
containing GABA are available commercially, 
their efficacy is limited due to low GABA 
permeability across the blood/brain barrier 
(Kakee et al., 2008). Inspired by work showing 
that serotonin levels are increased by 
consumption of serotonin precursors (i.e. 
tryptophan (Shabbir et al., 2013)), we asked 
whether consuming substances associated with 
the production of GABA could modulate the 
balance of inhibition and excitation in the brain. 
 
GABA functions as the primary inhibitory 
neurotransmitter in the mammalian nervous 
system. It is produced in the brain as a part of 
the GABA-glutamate cycle, with pyridoxine 
(vitamin B6) as a co-factor in this synthesis, and 
other substances such as vitamin B12 having a 
modulatory effect on its concentration (Ikeda et 
al., 1997). It is well established in 
neurophysiological work that evoked responses 
in early visual cortex are strongly modulated by 
GABA-ergic processes (Katzner et al., 2011; 
Morrone et al., 1987). Infusing a GABA 
antagonist (gabazine) into the cortex of 
anaesthetized cats has been shown to increase 
responsiveness by up to 300% (Katzner et al., 
2011). This Ôresponse gainÕ effect should 
provide a clear index of GABA availability in 
cortex, in that increasing GABA concentration 
should reduce the neural response evoked by 
visual stimuli to below normal levels. 
 
We measured steady-state visual evoked 
potentials (Norcia et al., 2015) using 
electroencephalography (EEG) as a baseline 
index of neural excitability. In this paradigm, 
flickering visual stimuli are displayed at 
different contrast levels, and a frequency-
locked response is recorded from posterior 
regions of the scalp over visual cortex (see 
Figure 1 for details). Participants then 
consumed either a yeast-extract substance rich 
in glutamate and B-vitamins, or a control 
substance (peanut butter), each day for one 
month (while also continuing their normal diet), 
followed by a repeat of the EEG measurements. 
We determined that the active substance 
contained around 116 times more vitamin B12, 
3 times more vitamin B6, and 1.85 times more 
glutamate than the control substance (see Table 
1 for further details). Any change in neural 
response as a consequence of the treatment is 
therefore likely to be due to these substances 
promoting increased GABA availability. 
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Table 1: Concentration of glutamate and B-vitamins in the two substances used in the experiment. Inhomogeneity 
of the peanut butter led to greater variability between analyses for the glutamate analysis (2 analytical replicates; 3 
subsamples, error term represents coefficient of variance). 
 
Nutrient Yeast-extract Peanut butter Ratio 
Vitamin B6 (Pyridoxine) 0.57 mg / 100 g 0.19 mg / 100 g 3.0 
Vitamin B12 (cyanocobalamin) 29 μg / 100 g 0.25 μg / 100 g 116.0 
Glutamate (as glutamic acid) 2.8 g / 100 g (±12%) 1.5 g / 100 g (±43%) 1.85 
 
 
 
 
Figure 1: Illustration of the steady-state visual evoked potential paradigm. A visual stimulus flickering in contrast at 
a defined temporal frequency (smooth black curve in panel a) will produce a modulation of the EEG waveform (blue 
trace in panel a) over posterior scalp regions (panel b) at the target frequency and its harmonics. The dependent 
variable is the amplitude in the Fourier spectrum at the flicker frequency, which shows excellent isolation from 
adjacent frequencies, implying high signal-to-noise ratios (panel c,d). The data used to produce this figure were 
averaged over 28 observers in the baseline condition (pre-treatment) at the highest target contrast (panels a-c) and 
for a condition in which a mask was shown in isolation (panel d). 
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2 Methods 
 
2.1 Participants 
 
A group of 28 adult volunteers (10 male, mean 
age 22) completed the study after providing 
written informed consent. They were assigned 
randomly to either the control or treatment 
group, and were not informed of the 
experimental hypotheses. Because the 
experiment involved viewing flickering stimuli, 
we ensured that participants did not have a 
history of epilepsy. We also confirmed that 
participants did not smoke, suffer from nut 
allergies, or use controlled substances 
recreationally. Procedures were approved by 
the research ethics committee of the 
Department of Psychology at the University of 
York. 
 
2.2 Apparatus and stimuli 
 
Stimuli were displayed using a gamma 
corrected ViewPixx display (VPixx 
Technologies Ltd., Montreal, Canada) running 
at 120 Hz. We recorded EEG signals at 1 kHz 
from 64 electrodes across the scalp (see Figure 
1b for electrode locations) using a Waveguard 
cap and the ASAlab system (ANT Neuroscan, 
Netherlands). Stimulus onset and condition was 
recorded on the EEG trace using a low-latency 
digital trigger. EEG signals were stored on disk 
for offline analysis. 
 
Stimuli were small patches of sine-wave 
grating, spatially curtailed by a raised cosine 
envelope (see Figure 1a for examples). Each 
patch had a spatial frequency of 0.5c/deg, and a 
diameter of 3deg. We tiled the patches across 
the display in a regular 17x9 grid separated by 
3 degrees of visual angle. The central element 
was removed to leave a space for an attentional 
control task, described below. To minimise 
adaptation, we randomised the orientation of the 
elements on each trial. Stimuli were presented 
using Matlab (The MathWorks Inc., 
Massachusetts, USA) and the Psychophysics 
Toolbox extensions, running on an Apple 
Macintosh computer. 
 
The yeast-extract substance was a 
commercially available spread (Marmite; 
Unilever Plc., London, UK) that is fortified with 
B-vitamins. The control substance was smooth 
peanut butter containing peanuts (97%), palm 
oil and salt. We tested 3 subsamples of both 
substances for glutamate content (following 24 
hour acid treatment to hydrolyse any peptide-
bound glutamic acid) using reverse-phase high 
pressure liquid chromatography (Penkman et 
al., 2008). During hydrolysis, glutamine 
undergoes rapid irreversible deamination to 
glutamic acid (Hill, 1965), so as it is not 
possible to distinguish these, they are reported 
as Glx. Since similar processes would likely 
occur during metabolisation, this was not a 
major concern. We also had the B-vitamin 
content assessed at an ISO17025 accredited 
laboratory in the UK. Detailed results of these 
analyses are presented in Table 1. 
 
2.3 Procedures 
 
Participants first completed four blocks of the 
EEG experiment. In each block, trials of 11 s 
duration were presented. Trials were presented 
in random order, with a 3 s inter-trial interval. 
There were 7 target contrast levels from 0% to 
64%, and 2 mask contrasts (0% and 32%). The 
target stimuli were cosine-phase sine-wave 
gratings that flickered sinusoidally in contrast 
between 0% and their nominal maximum at 7 
Hz. The mask stimuli were superimposed sine-
phase gratings of the same spatial frequency but 
orthogonal orientation to the targets, that 
flickered at 5 Hz. The effect of the 
orthogonally-presented mask stimuli is to 
suppress neural responses to the target stimuli, 
with higher GABA levels being thought to 
result in greater suppression (Morrone et al., 
1987). Each condition was repeated twice per 
block, resulting in 8 repetitions per observer. 
Next, participants were given a jar of either the 
active or placebo substance and instructed to 
consume 5 mL (one teaspoon full) daily for one 
month. Their diets were otherwise unchanged. 
At the end of this time they returned to the lab 
and repeated the same EEG experiment. 
Participants also completed an adherence 
questionnaire, which indicated that no 
participants forgot to take more than 4 doses 
across the four weeks, and when they did so 
typically (in all but one case) took a double dose 
the following day. A subset of 5 participants in 
the treatment group repeated the experiment a 
third time three months after the initial testing 
session. 
 
During all blocks of the experiment, 
participants completed a contrast discrimination 
task in the centre of the screen that was intended 
to maintain fixation and attention. The stimuli 
were the same sine-wave gratings that were 
used as a stimulus in the EEG experiment, but 
always with a horizontal orientation. The 
duration of each trial was 1400ms total, in 
which pairs of stimuli with different contrasts 
were presented sequentially for 500 ms (inter-
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stimulus-interval of 400 ms), flickering at 6 Hz. 
The task was to report which of the stimuli 
appeared higher in contrast. In one interval the 
contrast was drawn from a normal distribution 
with a mean of 0% and a standard deviation of 
2%. In the other interval the mean was 2% and 
the standard deviation was 2%. Negative 
contrasts constituted a phase reversal. 
 
We discarded the first 1000 ms of each EEG 
trial, and took the Fourier transform of the 
remaining 10000 ms. The amplitudes at the first 
and second harmonic of the target and mask 
frequencies were taken as dependent variables. 
We averaged amplitudes coherently across 
trials and across the four posterior electrode 
locations that gave the strongest signal 
(electrodes Oz, O1, O2 and POz, highlighted 
blue in Figure 1b). We then took the absolute 
value (discarding phase information) to 
calculate averages across observers and to 
perform statistical testing. Because the results 
of the treatment at the target frequency were 
similar in the 0% and 32% mask conditions (see 
Figure S1a,b), we ran a 4-way mixed ANOVA 
on these data (see supplementary table S1). At 
the mask frequency, there was no modulation in 
response when the mask contrast was 0%, but a 
substantial modulation when the mask contrast 
was 32% (see Figure S1c,d). We therefore ran 
two separate 3-way mixed ANOVAs for these 
conditions (see supplementary tables S2 & S3). 
Raw data are available online at: 
https://dx.doi.org/10.6084/m9.figshare.350741
0.v1 
 
3 Results 
 
The steady-state paradigm produced monotonic 
contrast response functions that were locked to 
the target frequency of 7 Hz (see Figures 1c and 
2a,b). When a second high-contrast component 
(which we term the ÔmaskÕ) was added 
flickering at a different frequency (5 Hz), it 
produced a strong response locked to its 
frequency (see Figures 1d and 2c,d). The mask 
response was suppressed by high target 
contrasts (downward trend in Figure 2c,d), 
consistent with results using similar stimulus 
arrangements in both humans and animals 
(Busse et al., 2009; Heeger, 1992). 
 
 
 
Figure 2: Steady-state EEG responses at the target (panel a,b) and mask (panel c,d) frequencies in both the placebo 
control group (left) and the treatment group (right). Each data point is the average of 14 participants, with shaded 
regions indicating ±1SE of the mean. 
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At the target temporal frequency (and at its 
second harmonic Ð see Figure S2 in 
supplementary information), evoked responses 
at high contrasts (> 8%) were reduced following 
consumption of yeast-extract, but not peanut 
butter (Figure 2a,b). This is supported by a 
significant interaction (F2.53,65.73 = 4.10, p < 0.05, 
partial η2 = 0.14) between substance (active vs. 
control), time (baseline vs. post-consumption) 
and target contrast (collapsing across mask 
contrast levels, which were similarly affected, 
see table S1 in supplementary information). The 
involvement of target contrast in the interaction 
is critical, as it demonstrates that only stimulus-
evoked responses were affected Ð the baseline 
ÔnoiseÕ levels when viewing a blank screen 
remained constant, ruling out nuisance 
variables such as practise effects and equipment 
changes. There was also no modulation of 
responses at the mask frequency when the target 
was presented alone (blue circles and squares in 
Figure 2c,d, see table S2).  
 
We replicated the critical effects at the mask 
temporal frequency (5 Hz), where a consistent 
reduction in amplitudes (average of 30%) was 
observed at all target contrast levels following 
treatment (Figure 2d), but not placebo (Figure 
2c). Interactions between substance and time 
(F1,26 = 8.46, p < 0.01, partial η
2 = 0.246) and 
between substance, time and contrast (F4.52,117.54 
= 3.06, p = 0.015, partial η2 = 0.105) were 
significant at the mask frequency (see 
supplementary table S3). 
 
Since visual responses are modulated by 
attention (Verghese et al., 2012), we considered 
whether subjects in the active group might have 
paid less attention to the display during their 
second testing session. Throughout all 
experiments, participants performed a 
challenging contrast discrimination task in the 
centre of the display to maintain fixation and 
attentional focus. We confirmed that 
performance remained constant across testing 
sessions for both the active (pre/post averages 
of 68% and 69% correct, p = 0.59) and control 
(pre/post averages of 67% and 66% correct, p = 
0.69) participants, ruling out changes in 
attention as a confounding factor in this study. 
We also assessed how long the effects might 
last by recalling a subset of participants from 
our treatment group and retesting them two 
months after they had ceased consuming the 
active substance. Response levels were still 
reduced, but no longer significantly different 
from baseline in this group at either temporal 
frequency, suggesting that the effects begin to 
wear off after resuming a normal diet (see 
Figure 3). 
 
Figure 3: Data from a subset of 5 participants in the 
treatment group who returned after a further two 
months during which they did not consume the active 
substance. The effect of the treatment after one 
month is still apparent for this subgroup (compare 
circles and squares at high contrast in panel a). At 7 
Hz there was a main effect of time (F1,4 = 8.16, p < 
0.05, partial η2 = 0.671) and time*contrast interaction 
(F6,24 = 4.58, p < 0.01, partial η
2 = 0.534). However, 
following the washout period of 2 months, responses 
had begun to return towards baseline (triangles in 
panel a, green circles in panel b), and were no longer 
significant (p>0.05 for main effect of time and 
time*contrast interactions). These results suggest 
that the effects might be relatively long lasting, in the 
order of weeks or months. 
 
4 Discussion 
 
Using a steady-state EEG paradigm, we found 
that a dietary intervention had a significant 
effect on the brainÕs response to visual stimuli, 
compared with consumption of a placebo. This 
was unlikely to be a consequence of attentional 
lapses, and the effects were reduced after two 
months of resuming a normal diet. These 
findings are consistent with an increase in the 
availability of GABA in visual areas of the 
brain that inhibits the excitability of neurons 
responsive to the stimulus (Katzner et al., 
2011). Although we did not observe clear 
Smith, Wade, Penkman & Baker (2017) Journal of Psychopharmacology 
doi: 10.1177/0269881117699613 
This post-print version was created for open access dissemination through institutional repositories 
changes in suppression between stimuli (i.e. the 
reduction in response to the target caused by 
presentation of the mask did not substantially 
increase following treatment, as shown in 
Figure S1b), we also anticipate that dietary 
modulation of neural inhibition will prove 
important for understanding basic suppressive 
processes in the healthy brain (Morrone et al., 
1987). 
 
Patients with epilepsy show increased visual 
responses using a similar steady-state paradigm 
to that used here (Porciatti et al., 2000; Tsai et 
al., 2011). This raises the possibility that dietary 
interventions geared towards increasing GABA 
concentration might reduce excitability to 
normal levels, and potentially alleviate some 
symptoms of the disorder such as seizure 
frequency (particularly for photosensitive 
epileptics). This might be of particular utility in 
treating patients who either do not respond to 
traditional medication, or who cannot take it for 
other reasons (e.g. pregnancy, or interactions 
with other drugs). The apparent involvement of 
GABA in other neurological and mental health 
conditions (Honig et al., 1988; Nemeroff, 2003; 
Robertson et al., 2016) suggests further 
potential for deployment of dietary 
interventions. 
 
Could some alternative pathway be responsible 
for our results? One possibility is that vitamin 
B12 is involved as a co-factor (Briani et al., 
2013) in the production of myelin (the fatty 
sheath that insulates axons and improves nerve 
conductance). Increased myelin should speed 
up transmission of signals through the nervous 
system, yet an additional analysis of the phase 
component of our steady-state data indicated no 
significant change in the response lag at the 
mask frequency following treatment (t-test for 
mask alone, t=-1.55, df =13, p=0.15; the mask 
frequency was chosen because it was slower 
than the target frequency (5Hz vs 7Hz) so will 
have fewer wraparound artefacts). Changes in 
myelin could conceivably influence signal 
amplitudes, though this would presumably be 
through increased signal fidelity (reduced 
noise). This account would predict increased 
amplitudes following supplementation, yet the 
effect of the treatment was to reduce amplitudes 
(see Figure 2b,d). We intend to investigate this 
possibility further in future studies using 
structural MRI. It is also conceivable that other 
micronutrients present in yeast-extract (such as 
tyrosine, tryptophan, phenylanaline, niacin, 
folic acid and riboflavin) could have affected 
our results. However, we are not aware of any 
plausible pathway by which these nutrients 
could affect excitation and inhibition, and their 
concentration in the active substance is not 
dramatically higher than in a typical diet. 
 
The findings of this study suggest that dietary 
intervention may modulate cortical excitation 
and inhibition, which may be due to increased 
GABA concentration. If this is the case, 
although previous studies have shown that 
drugs such as lorazepam can transiently affect 
both GABA concentration and perception (van 
Loon et al., 2013), this is the first demonstration 
(to our knowledge) of dietary modulation of the 
same pathways. We anticipate that the 
processes involved will operate over a longer 
time-scale, and perhaps be more stable than 
drug treatments. Since our active substance 
contained several ingredients, we hope to 
determine from future work which substance(s) 
are key to modulating levels of this 
neurotransmitter in the cortex. Though it is 
possible that the effects may be due to 
substances present in the yeast extract other 
than those highlighted here, the dramatically 
high concentrations of vitamin B12 in our active 
substance (see Table 1), as well as potentially 
high levels of marginal deficiency in the 
population (Allen, 2009), make this nutrient the 
most likely candidate for driving our effects. 
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8 Supplementary Material 
 
Table S1: Full ANOVA table for the 7 Hz response, corresponding to the data in Figure S1a,b. The model was a 4-
way mixed ANOVA, with between subjects factor of substance (treatment vs control) and within subjects factors of 
time (pre and post treatment), mask contrast (0 and 32%) and target contrast (7 levels). Significant effects are 
highlighted in bold. Non-integer degrees of freedom indicate Greenhouse-Geisser corrected values. 
 F-ratio Num df Denom df p Partial η2 
Substance 0.22 1 26 0.882 0.001 
Time 4.37 1 26 0.046 0.139 
Mask contrast 4.21 1 26 0.050 0.144 
Target contrast 46.61 1.4 36.53 <0.001 0.642 
Substance * time 1.89 1 26 0.182 0.068 
Substance * mask 0.03 1 26 0.873 0.001 
Substance * target 0.35 1.4 36.53 0.630 0.013 
Time * mask 3.94 1 26 0.058 0.132 
Time * target 4.88 2.53 65.73 0.006 0.158 
Mask * target 8.77 2.55 66.27 <0.001 0.252 
Substance * time * mask 0.27 1 26 0.608 0.010 
Substance * time * target 4.10 2.53 65.73 0.014 0.136 
Substance * mask * target 0.15 2.55 66.27 0.903 0.006 
Time * mask * target 0.59 3.45 89.70 0.645 0.022 
Substance * time * mask * 
target 
1.53 3.45 89.70 0.207 0.056 
 
Table S2: Full ANOVA table for the 5 Hz response in the 0% mask contrast condition, corresponding to the blue 
data points in Figure S1c,d. The model was a 3-way mixed ANOVA, with between subjects factor of substance 
(treatment vs control) and within subjects factors of time (pre and post treatment) and target contrast (7 levels). No 
effects reached significance. Non-integer degrees of freedom indicate Greenhouse-Geisser corrected values. 
 F-ratio Num df Denom df p Partial η2 
Substance 0.14 1 26 0.714 0.005 
Time 3.04 1 26 0.093 0.105 
Target contrast 2.02 1.78 46.30 0.149 0.072 
Substance * time 3.31 1 26 0.080 0.113 
Substance * target 0.96 1.78 46.30 0.457 0.035 
Time * target 0.54 1.71 44.32 0.559 0.020 
Substance * time * target 0.70 1.71 44.32 0.482 0.026 
 
Table S3: Full ANOVA table for the 5Hz response in the 32% mask contrast condition, corresponding to the 
red/orange data points in Figure S1c,d. The model was a 3-way mixed ANOVA, with between subjects factor of 
substance (treatment vs control) and within subjects factors of time (pre and post treatment) and target contrast (7 
levels). Significant effects are highlighted in bold. Non-integer degrees of freedom indicate Greenhouse-Geisser 
corrected values. 
 F-ratio Num df Denom df p Partial η2 
Substance 2.79 1 26 0.107 0.097 
Time 4.39 1 26 0.046 0.145 
Target contrast 29.50 2.08 53.99 <0.001 0.532 
Substance * time 8.46 1 26 0.007 0.246 
Substance * target 3.01 2.08 53.99 0.056 0.104 
Time * target 1.78 6 156 0.107 0.064 
Substance * time * target 3.06 4.52 117.54 0.015 0.105 
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Figure S1: Reproduction of Figure 2 with data added at the target frequency for the 32% mask condition (red 
diamonds and orange triangles in panels a,b). These data were removed from the main figure to reduce clutter, but 
show the same pattern of reduced amplitudes at high target contrasts following treatment for the treatment group 
(panel b), but not the control group (panel a). 
 
 
Figure S2: Steady-state responses at the second harmonic of the target frequency (14 Hz), in the same format as 
Figure S1a,b. There was an amplitude reduction in the treatment group at high contrasts for the post-consumption 
phase (squares and triangles). Response at the second harmonic of the mask frequency (10 Hz) fell within the alpha 
band and were therefore noisier and less reliable (not shown). 
 
